NeuroMetrix (NASDAQ:NURO) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research report sent to investors on Thursday. The firm issued a sell rating on the medical device company’s stock.

NeuroMetrix Trading Up 0.4 %

Shares of NURO stock opened at $4.02 on Thursday. The company has a market cap of $8.20 million, a PE ratio of -0.87 and a beta of 2.20. NeuroMetrix has a 12-month low of $2.66 and a 12-month high of $4.73. The business’s fifty day simple moving average is $4.02 and its 200-day simple moving average is $3.88.

NeuroMetrix (NASDAQ:NURO) last released its quarterly earnings results on Tuesday, November 5th. The medical device company reported ($0.75) EPS for the quarter. The business had revenue of $0.59 million during the quarter. NeuroMetrix had a negative net margin of 203.71% and a negative return on equity of 42.56%. During the same period in the previous year, the business posted ($1.66) EPS.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.